Working… Menu

Effects of Inhaled Nitric Oxide in the Treatment of Acute Hypoxemic Respiratory Failure (AHRF) in Pediatrics

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00041561
Recruitment Status : Terminated (Study stopped due to poor enrollment)
First Posted : July 11, 2002
Last Update Posted : July 26, 2016
Information provided by (Responsible Party):

Brief Summary:
The purpose of this study is to determine the effect of nitric oxide for inhalation on the duration of mechanical ventilation in pediatric patients with AHRF.

Condition or disease Intervention/treatment Phase
Respiratory Insufficiency Anoxemia Drug: Nitrogen gas Drug: inhaled nitric oxide Phase 3

Detailed Description:
Patients will receive 5-ppm study gas (nitric oxide for inhalation or placebo) until Day 28 or extubation, whichever comes first. The following will be performed / recorded at specified times during the study: arterial blood gases, ventilator settings, methemoglobin, PRISM III score, and patient positioning. Selected centers will also be performing plasma cytokine assays, broncho-alveolar lavage fluid assays and a 6 month follow-up assessment.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 55 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: The Effects of Inhaled Nitric Oxide in the Treatment of Acute Hypoxemic Respiratory Failure (AHRF) In Pediatrics
Study Start Date : January 2002
Actual Primary Completion Date : December 2004
Actual Study Completion Date : December 2004

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Placebo Comparator: 2
Nitrogen gas
Drug: Nitrogen gas
Nitrogen gas will be given at 5ppm until Day 28 or extubation

Experimental: 1
Inhaled Nitric Oxide
Drug: inhaled nitric oxide
inhaled nitric oxide will be given at 5 ppm until day 28 or extubation
Other Name: INOmax®

Primary Outcome Measures :
  1. arterial blood gases [ Time Frame: baseline through 24 hours and extubation ]

Secondary Outcome Measures :
  1. methemoglobin [ Time Frame: baseline, hour 4 and 24 hours ]
  2. broncho-alveolar lavage fluid [ Time Frame: baseline, 48 hours and day 5 ]
  3. Prone position [ Time Frame: baseline then daily ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   up to 16 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria:

  • Admitted to pediatric intensive care unit and have the diagnosis of acute respiratory failure
  • 44 weeks post conceptional age to 16 years of age
  • Oxygenation Index (OI) >=12 cm H2O/mmHg (as determined by two separate measurement taken 30 minutes to 4 hours apart)
  • Recent chest x-ray (within 24 hours) showing at least unilateral infiltrations
  • Mechanically ventilated <= 7 days

Exclusion criteria:

  • Immunocompromised
  • Received a bone marrow transplant
  • Active oncological condition
  • Persistent right to left intracardiac shunt
  • Cardiovascular surgery within the last 14 days
  • Status asthmaticus
  • Decision by primary care physician not to provide full support
  • Received treatment with nitric oxide for inhalation or other investigational medications within 24 hours prior to study initiation, participating in surfactant trials
  • Chronically ventilated
  • Pregnant

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00041561

Layout table for location information
United States, California
Chrildren's Hospital of Orange County
Orange, California, United States, 92868
Stanford University Medical Center
Stanford, California, United States, 94305
United States, Colorado
The Children's Hospital
Denver, Colorado, United States, 80218
United States, Florida
Nemours Children's Clinic
Orlando, Florida, United States, 32806
United States, Georgia
Children's Healthcare of Atlanta at Egleston
Atlanta, Georgia, United States, 30322
United States, Illinois
University of Chicago, Children's Hospital
Chicago, Illinois, United States, 60637
United States, Louisiana
Louisiana State University Health Sciences Center - Shreveport
Shreveport, Louisiana, United States, 71103
United States, Maryland
The Johns Hopkins Hospital
Baltimore, Maryland, United States, 21287
United States, New York
Children's Hospital at Montefiore
Bronx, New York, United States, 10467
New York Presbyterian Hospital
New York, New York, United States, 10021
United States, Ohio
Children's Hospital Medical Center of Akron
Akron, Ohio, United States, 44308
The Cleveland Clinic Foundation
Cleveland, Ohio, United States, 44195
Children's Hospital
Columbus, Ohio, United States, 43205
United States, Oregon
Oregon Health and Science University
Portland, Oregon, United States, 97239
United States, South Carolina
The Medical University of South Carolina
Charleston, South Carolina, United States, 29425
United States, Virginia
University of Virginia Pediatric Critical Care
Charlottesville, Virginia, United States, 22908
Sponsors and Collaborators
Layout table for investigator information
Study Director: James Baldassarre, MD Mallinckrodt

Layout table for additonal information
Responsible Party: Mallinckrodt Identifier: NCT00041561     History of Changes
Other Study ID Numbers: INOT-11
First Posted: July 11, 2002    Key Record Dates
Last Update Posted: July 26, 2016
Last Verified: July 2016
Keywords provided by Mallinckrodt:
Acute hypoxemic respiratory failure
Additional relevant MeSH terms:
Layout table for MeSH terms
Respiratory Insufficiency
Pulmonary Valve Insufficiency
Respiration Disorders
Respiratory Tract Diseases
Heart Valve Diseases
Heart Diseases
Cardiovascular Diseases
Nitric Oxide
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Free Radical Scavengers
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Endothelium-Dependent Relaxing Factors
Vasodilator Agents
Protective Agents